Strategic growth Target medical institutions and hospitals performing bronchoscopic procedures and tissue sampling, highlighting Van Gogh as a real-time, intraprocedural diagnostic tool that preserves tissue for downstream histology and molecular analyses.

Clinical validation Leverage its clinically validated claims to pursue partnerships with reference centers and KOLs to drive clinical adoption, expand use cases beyond bronchoscopy into other biopsy workflows.

Regulatory momentum Monitor FDA registrations and milestones to align sales cycles with regulatory success, and position CelTivity as a compliant, ready-to-scale solution for U.S. and international markets.

Early revenue signals Capitalize on current revenue and FDA-registered system to upsell upgrades, service contracts, and expanded site deployments within existing customers and adjacent medical centers.

Strategic partnerships Engage with large medtech and diagnostic company ecosystems (e.g., downstream labs and pathology networks) to co-market or bundle DCI with existing imaging, pathology, and molecular workflows.